CPS will enable earlier identification and therapy guidance for heart failure patients. Credit: Africa Studio / Shutterstock.com.

Cardiac diagnostic company Sensydia has received a $3m grant to accelerate the development of its artificial intelligence (AI)-driven cardiac assessment platform, named Cardiac Performance System (CPS).

The Fast-Track Small Business grant was awarded by the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sensydia will use the non-dilutive funding to develop and clinically assess the machine learning algorithms for the CPS.

The system is intended to facilitate earlier identification and treatment guidance for patients suffering from pulmonary hypertension and heart failure.

Sensydia chief medical officer Dr Aman Mahajan said: “We are honoured to be a recipient of this competitive award from the NIH/NHLBI and look forward to unlocking the capabilities of this AI-based cardiac assessment to provide personalised care to patients suffering from heart disease.”

The grant will be provided across two phases. Under phase I, the company will be allocated a budget of about $600,000.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This will be followed by phase II with a funding of $2.4m, upon achieving certain milestones.

Sensydia is engaged in the development of AI-based solutions for the diagnosis and management of cardiopulmonary diseases and last month, the company secured $8m in venture funding to advance its CPS cardiac assessment platform.

In 2018, the company received 510(k) clearance from the US Food and Drug Administration (FDA) to non-invasively measure ejection fraction using first-generation hardware.

Last year, it secured breakthrough device status from the FDA for the CPS for the measurement of three more cardiac measures, including pulmonary capillary wedge pressure, pulmonary artery pressure and cardiac output.